6304-56-9

Usage

Uses

Used in Nutritional Supplements:
1-CYCLOHEXYL-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID is used as a dietary supplement for its essential role in protein synthesis and its potential health benefits, including supporting cardiovascular health and promoting healthy skin and joint function.
Used in Food Industry:
1-CYCLOHEXYL-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID is used as a natural amino acid in various foods, including meat, dairy, and legumes, to enhance their nutritional value and support the synthesis of proteins and enzymes.
Used in Pharmaceutical Industry:
1-CYCLOHEXYL-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID is used as a key building block for collagen, which is an important structural component of connective tissues, skin, and bones. It is utilized in the development of pharmaceutical products targeting skin health, joint function, and connective tissue support.
Used in Cosmetics Industry:
1-CYCLOHEXYL-5-OXO-PYRROLIDINE-3-CARBOXYLIC ACID is used as an ingredient in cosmetic products for its potential benefits in promoting healthy skin and supporting collagen synthesis, contributing to skin elasticity and hydration.

InChI:InChI=1/C11H17NO3/c13-10-6-8(11(14)15)7-12(10)9-4-2-1-3-5-9/h8-9H,1-7H2,(H,14,15)/p-1/t8-/m1/s1

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 108-91-8 cyclohexylamine 

Downstream Products

• 886615-26-5 1-cyclohexyl-4-(hydroxymethyl)pyrrolidin-2-one 
• 1181577-49-0 1-cyclohexyl-5-oxo-pyrrolidine-3-carbonyl chloride 

Relevant academic research and scientific papers

PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS

Simple organic structures, organic/inorganic polymers, and other substrates have been made, all of which have at least one pyrrolidone moiety present, and found to exhibit low toxicity, low complement activation features and may be used to reduce protein

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses compounds of Formula I: (I) having 11beta -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis

In view of the worldwide spread of multidrug resistance of Mycobacterium tuberculosis, there is an urgent need to discover antituberculosis agent with novel structures. InhA, the enoyl acyl carrier protein reductase (ENR) from M. tuberculosis, is one of t

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives

A novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1- methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3- carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC 50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.

CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

A compound of the formula: wherein R1 is a hydrocarbon group, R2 is a hydrocarbon group having 2 or more carbon atoms, where R1 and R2 may in combination form, together with an adjacent nitrogen atom, a ring optionally having a substituent or substituents, R3 is a hydrocarbon group optionally having a substituent or substituents or a heterocyclic group optionally having a substituent or substituents, R4 is a hydrogen atom, a hydrocarbon group, a heterocyclic group and the like, E is a divalent chain hydrocarbon group and the like, G is CO or SO2, J is a nitrogen atom, a methine group and the like, and Q and R are each a divalent chain C1-3 hydrocarbon group and the like, and a salt thereof show a superior CCR5 antagonistic activity and are useful as agents for the prophylaxis or treatment of HIV infection of human peripheral blood mononuclear cells, particularly AIDS.